![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Parabolic Drugs Limited Panchkula District In, based in India, is a pharmaceutical company that stands out with its certifications from EDQM and WHO-GMP.
One of their significant offerings is Flucloxacillin sodium monohydrate, Process II, supported by a 'Withdrawn by EDQM Failure to CEP procedure' Certificate of Suitability (CEP) with the number R0-CEP 2010-311 - Rev 00
This Chemical Type CEP, issued on January 24, 2013, remains in force until July 29, 2015, ensuring its reliability within the pharmaceutical industry.
Substance Number 668 associated with this CEP further emphasizes